VYCOR MEDICAL INC (VYCO) Form 10-Q — Aug 14, 2026
Vycor Medical's Q2 2026 10-Q shows revenue of $418,264, down 16% year over year, with the core Vycor Medical neurosurgery segment down 17% on lumpy international orders. The quarter swung to a net loss of $22,288 from a $23,887 profit a year ago, though the six-month net loss narrowed to $2,180. The filing carries explicit going-concern language: the company holds a working capital deficiency of $4,294,543 against just $158,907 in cash and says it may not have sufficient cash to meet its needs through August 31, 2027 without new debt or equity funding.
Key figures
- Eps
- -$0.00 basic and diluted
- Revenue
- 876804
- Total Debt
- Notes payable of $931,025: $303,674 other notes, $493,373 related-party notes, $133,978 SBA EIDL long-term loan
- Revenue Yoy
- -6% for six months ended June 30, 2026; -16% for Q2 2026
- Total Assets
- 813174
- Cash Position
- 158907
- Shares Outstanding
- 33372796
- Revenue q2 2026
- 418264
- Gross margin pct
- 82
- Net income q2 2025
- 23887
- Revenue q2 yoy pct
- -16
- Euroamerican maturity
- December 31, 2026
- Related party liabilities
- 3800538
- Euroamerican note principal
- 300000
- Preferred dividends payable
- 3081515
- Euroamerican accrued interest
- 592833
- Operating cash flow six months
- 94579
- Cash paid for interest six months
- 47771
AI analysis
Red flags7 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.